Results 191 to 200 of about 157,438 (357)

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]

, 2001
McMurray, John J.V.
core   +1 more source

Do ACE‐inhibitors suppress tumour necrosis factor‐α production in advanced chronic renal failure? [PDF]

, 1999
Peter Stenvinkel, Patrik Andersson, T. Wang, Bengt Lindholm, Jonas Bergström, Jan Palmblad, Olof Heimbürger, Tommy Cederholm   +7 more
openalex   +1 more source

ACE-Inhibitor or ARB-Induced Refractory Hypotension Treated With Vasopressin in Patients Undergoing General Anesthesia for Dentistry: Two Case Reports. [PDF]

Anesth Prog, 2022
Waters CM, Pelczar K, Adlesic EC, Schwartz PJ, Giovannitti JA.   +4 more
europepmc   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study [PDF]

, 1997
Kristian Waldec, Bengt Lindberg, Katarina Persson, Karl‐Erik Andersson   +3 more
openalex   +1 more source

Pharmacogenomic biomarkers of ACE inhibitor-induced cough in a multi-ethnic UAE cohort. [PDF]

Front Pharmacol
Altoum SM, Al-Mahayri ZN, Khasawneh LQ, Alqasrawi MN, Dabaghie L, Hamza D, Ali BR.   +6 more
europepmc   +1 more source

DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema. [PDF]

J Investig Med High Impact Case Rep, 2021
Ejikeme C, Nwachukwu C, Viechweg JL, Ejikeme I, Brescia M.   +4 more
europepmc   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease [PDF]

, 1996
Yoshihiko Kanno, Hiromichi Suzuki, Hirokazu Okada, Tsuneo Takenaka, T Saruta   +4 more
openalex   +1 more source